Cost-Effectiveness Analysis of Peginterferon Beta-1a Vs. First-Line Injectable Disease-Modifying Therapies For The Treatment of Relapsing-Remitting Multiple Sclerosis In Spain

Ruiz, Laura León; Toro-Díaz, Hector; Cele, C; Hernández, Luis; Harrington, Amanda

doi:10.1016/j.jval.2017.08.1948

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Geographically, of the 127 included studies, a majority were from the USA ( n = 29), followed by the UK ( n = 17) and Spain ( n = 10) [ 24 , 50 , 53 , 59 , 75 – 80 ]. HTA reports were mostly from Scotland ( n = 11) [ 29 , 30 , 81 – 89 ], followed by England ( n = 8) [ 90 – 97 ], and Canada ( n = 7) [ 28 , 98 – 103 ] (Fig.…”

Section: Resultsmentioning

confidence: 99%

“…Geographically, of the 127 included studies, a majority were from the USA (n = 29), followed by the UK (n = 17) and Spain (n = 10) [24,50,53,59,[75][76][77][78][79][80]. HTA reports were mostly from Scotland (n = 11) [29,30,[81][82][83][84][85][86][87][88][89], followed by England (n = 8) [90][91][92][93][94][95][96][97], and Canada (n = 7) [28,[98][99][100][101][102][103] (Fig.…”

Section: Study Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review

Wiyani¹,

Badgujar

Khurana³

et al. 2021

Neurol Ther

View full text Add to dashboard Cite

Introduction: The introduction of diseasemodifying therapies (DMTs) for relapsing multiple sclerosis (RMS) over the last two decades has prompted the economic assessments of these treatments by reimbursement authorities. The aim of this systematic literature review was to evaluate the modeling approach and data sources used in economic evaluations of DMTs for RMS, identify differences and similarities, and explore how economic evaluation models have evolved over time. Methods: MEDLINEÒ, EmbaseÒ, and EBM Reviews databases were searched using OvidÒ Platform from database inception on 25 December 2019 and subsequently updated on 17 February 2021. In addition, health technology assessment agency websites, key conference proceedings, and gray literature from relevant

show abstract